Free Trial

Purple Biotech (PPBT) Competitors

Purple Biotech logo
$2.27 +0.05 (+2.25%)
Closing price 03:59 PM Eastern
Extended Trading
$2.24 -0.03 (-1.32%)
As of 05:15 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

PPBT vs. CING, ELEV, AYTU, BCAB, ADAP, MBRX, CASI, QTTB, FNCH, and PASG

Should you be buying Purple Biotech stock or one of its competitors? The main competitors of Purple Biotech include Cingulate (CING), Elevation Oncology (ELEV), Aytu BioPharma (AYTU), BioAtla (BCAB), Adaptimmune Therapeutics (ADAP), Moleculin Biotech (MBRX), CASI Pharmaceuticals (CASI), Q32 Bio (QTTB), Finch Therapeutics Group (FNCH), and Passage Bio (PASG). These companies are all part of the "pharmaceutical products" industry.

Purple Biotech vs. Its Competitors

Purple Biotech (NASDAQ:PPBT) and Cingulate (NASDAQ:CING) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their earnings, media sentiment, valuation, dividends, risk, institutional ownership, analyst recommendations and profitability.

Purple Biotech currently has a consensus price target of $33.00, suggesting a potential upside of 1,353.74%. Cingulate has a consensus price target of $26.00, suggesting a potential upside of 551.63%. Given Purple Biotech's higher possible upside, analysts plainly believe Purple Biotech is more favorable than Cingulate.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Purple Biotech
0 Sell rating(s)
0 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
3.00
Cingulate
0 Sell rating(s)
0 Hold rating(s)
5 Buy rating(s)
0 Strong Buy rating(s)
3.00

9.6% of Purple Biotech shares are held by institutional investors. Comparatively, 41.3% of Cingulate shares are held by institutional investors. 3.0% of Purple Biotech shares are held by insiders. Comparatively, 5.3% of Cingulate shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

In the previous week, Cingulate had 15 more articles in the media than Purple Biotech. MarketBeat recorded 15 mentions for Cingulate and 0 mentions for Purple Biotech. Purple Biotech's average media sentiment score of 0.00 beat Cingulate's score of -0.06 indicating that Purple Biotech is being referred to more favorably in the media.

Company Overall Sentiment
Purple Biotech Neutral
Cingulate Neutral

Purple Biotech is trading at a lower price-to-earnings ratio than Cingulate, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Purple BiotechN/AN/A-$7.24M-$0.42-5.40
CingulateN/AN/A-$15.55M-$4.10-0.97

Purple Biotech has a beta of 0.49, meaning that its stock price is 51% less volatile than the S&P 500. Comparatively, Cingulate has a beta of -0.74, meaning that its stock price is 174% less volatile than the S&P 500.

Purple Biotech's return on equity of -14.00% beat Cingulate's return on equity.

Company Net Margins Return on Equity Return on Assets
Purple BiotechN/A -14.00% -12.52%
Cingulate N/A -211.87%-131.66%

Summary

Purple Biotech beats Cingulate on 7 of the 12 factors compared between the two stocks.

Get Purple Biotech News Delivered to You Automatically

Sign up to receive the latest news and ratings for PPBT and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding PPBT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

PPBT vs. The Competition

MetricPurple BiotechMED IndustryMedical SectorNASDAQ Exchange
Market Cap$5.88M$3.11B$5.74B$9.56B
Dividend YieldN/A2.23%4.53%4.08%
P/E Ratio-5.4020.4030.4525.16
Price / SalesN/A238.54392.5887.64
Price / CashN/A42.3737.0358.50
Price / Book0.187.918.956.21
Net Income-$7.24M-$54.72M$3.26B$265.38M
7 Day Performance-1.73%1.63%1.06%-1.13%
1 Month Performance-18.35%5.86%4.31%-0.71%
1 Year PerformanceN/A8.70%28.40%18.89%

Purple Biotech Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
PPBT
Purple Biotech
1.4984 of 5 stars
$2.27
+2.3%
$33.00
+1,353.7%
N/A$5.88MN/A-5.4020
CING
Cingulate
2.4844 of 5 stars
$4.05
-2.9%
$26.00
+542.0%
-70.8%$21.95MN/A-0.4820Earnings Report
Short Interest ↑
ELEV
Elevation Oncology
1.3925 of 5 stars
$0.37
flat
$2.62
+616.9%
N/A$21.62MN/A-0.4540
AYTU
Aytu BioPharma
3.6331 of 5 stars
$2.24
-5.5%
$10.00
+346.4%
-21.8%$21.27M$81M-3.11160Positive News
BCAB
BioAtla
2.3067 of 5 stars
$0.36
+2.8%
$5.00
+1,279.3%
-80.1%$20.60M$11M-0.3360
ADAP
Adaptimmune Therapeutics
2.125 of 5 stars
$0.09
+10.7%
$1.35
+1,475.4%
-94.6%$20.54M$178.03M-0.32490Insider Trade
Analyst Revision
Gap Down
MBRX
Moleculin Biotech
3.0276 of 5 stars
$0.62
-7.8%
$4.00
+543.1%
-78.2%$20.38MN/A0.0020
CASI
CASI Pharmaceuticals
3.586 of 5 stars
$1.73
+6.1%
$4.00
+131.2%
-64.2%$20.05M$28.54M-0.68180Upcoming Earnings
QTTB
Q32 Bio
2.5917 of 5 stars
$1.79
+9.8%
$12.17
+579.7%
-95.3%$19.88M$1.16M-0.4239News Coverage
Short Interest ↓
Gap Down
FNCH
Finch Therapeutics Group
N/A$12.24
-1.6%
N/A+8.2%$19.66MN/A-1.39190
PASG
Passage Bio
3.8602 of 5 stars
$5.90
-5.9%
$150.00
+2,442.4%
-47.3%$19.56MN/A-0.29130

Related Companies and Tools


This page (NASDAQ:PPBT) was last updated on 8/21/2025 by MarketBeat.com Staff
From Our Partners